Welcome to LookChem.com Sign In|Join Free

CAS

  • or

888504-28-7

Post Buying Request

888504-28-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • High Quality 99% 888504-28-7 7,8-difluoro-6,11-dihydro-dibenzo [b, e] thieno-11-alcohol Manufacturer

    Cas No: 888504-28-7

  • USD $ 0.1-0.1 / Gram

  • 1 Gram

  • 100 Metric Ton/Year

  • Xi'an Xszo Chem Co., Ltd.
  • Contact Supplier

888504-28-7 Usage

Chemical Properties

Off-White Solid

Uses

Different sources of media describe the Uses of 888504-28-7 differently. You can refer to the following data:
1. An intermediate in the preparation of HIV-integrase inhibitors.
2. An intermediate in the preparation of HIV-integrase inhibitors

Check Digit Verification of cas no

The CAS Registry Mumber 888504-28-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,8,5,0 and 4 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 888504-28:
(8*8)+(7*8)+(6*8)+(5*5)+(4*0)+(3*4)+(2*2)+(1*8)=217
217 % 10 = 7
So 888504-28-7 is a valid CAS Registry Number.
InChI:InChI=1/C4H4N2O3.K/c1-2-5-6-3(9-2)4(7)8;/h1H3,(H,7,8);/q;+1/p-1

888504-28-7 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Aldrich

  • (CBR01107)  5-Methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt  AldrichCPR

  • 888504-28-7

  • CBR01107-1G

  • 4,512.69CNY

  • Detail

888504-28-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name potassium,5-methyl-1,3,4-oxadiazole-2-carboxylate

1.2 Other means of identification

Product number -
Other names 5-Methyl-1,3,4-oxadiazole-2-carboxylate,potassium salt

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:888504-28-7 SDS

888504-28-7Synthetic route

5-methyl-1,3,4-oxadiazole-2-carboxylic acid ethyl ester
37641-36-4

5-methyl-1,3,4-oxadiazole-2-carboxylic acid ethyl ester

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

Conditions
ConditionsYield
With potassium trimethylsilonate In diethyl ether at 20℃;100%
With potassium hydroxide In ethanol; water at 10 - 20℃; for 0.666667h;95%
With potassium trimethylsilonate In diethyl ether at 20℃;73%
5-methyl-1,2,3,4-tetrazole
4076-36-2

5-methyl-1,2,3,4-tetrazole

Ethyl oxalyl chloride
4755-77-5

Ethyl oxalyl chloride

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

Conditions
ConditionsYield
Stage #1: 5-methyl-1,2,3,4-tetrazole; Ethyl oxalyl chloride With triethylamine In toluene at 0 - 65℃; for 3h;
Stage #2: With potassium hydroxide; water In ethanol at 10 - 20℃; for 1.16667h;
90.8%
Stage #1: 5-methyl-1,2,3,4-tetrazole; Ethyl oxalyl chloride With triethylamine In toluene at 0 - 5℃; for 1h;
Stage #2: In toluene at 50 - 65℃; for 1.66667 - 1.83333h;
Stage #3: With potassium hydroxide In ethanol; water at 10 - 20℃; for 1.16667h;
90.8%
5-methyl-[1,3,4]oxadiazol carboxylic acid potassium salt
37641-35-3

5-methyl-[1,3,4]oxadiazol carboxylic acid potassium salt

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

Conditions
ConditionsYield
With potassium hydroxide; water In ethanol at 20℃; for 1.16667h;
C6H8N4O3

C6H8N4O3

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

Conditions
ConditionsYield
Stage #1: C6H8N4O3 In toluene at 50 - 70℃; Large scale reaction;
Stage #2: With potassium hydroxide In ethanol; water at 10 - 20℃;
4.48 kg
With potassium hydroxide In ethanol; water at 10℃; for 0.5h;8.0 g
With potassium hydroxide In ethanol; water for 2h;3.62 g
5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

5-methyl-1,3,4-oxadiazole-2-carboxylic acid chloride
889131-28-6

5-methyl-1,3,4-oxadiazole-2-carboxylic acid chloride

Conditions
ConditionsYield
With phosgene; N,N-dimethyl-formamide In toluene at 0 - 5℃; for 1.5h;100%
With oxalyl dichloride; N,N-dimethyl-formamide In acetonitrile at 0 - 5℃; for 1.33333h;
With oxalyl dichloride; N,N-dimethyl-formamide In acetonitrile at 0℃; for 2.33333h; Product distribution / selectivity;
5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

2-(2-aminopropan-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carbox-amide methanesulfonate

2-(2-aminopropan-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carbox-amide methanesulfonate

raltegravir
518048-05-0

raltegravir

Conditions
ConditionsYield
Stage #1: 5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt With oxalyl dichloride; N,N-dimethyl-formamide In toluene at 0 - 5℃; for 1.5h; Inert atmosphere;
Stage #2: 2-(2-aminopropan-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carbox-amide methanesulfonate With triethylamine In toluene; acetonitrile at 20 - 55℃;
87%
5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

C44H58N6O9S2

C44H58N6O9S2

C43H52N8O9S2

C43H52N8O9S2

Conditions
ConditionsYield
Stage #1: C44H58N6O9S2 With hydrogenchloride In isopropyl alcohol at 0 - 20℃;
Stage #2: 5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt With 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In dichloromethane at 30℃; for 6h; Inert atmosphere;
60%
5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7-dihydro-4H-spiro[pyrimido[2,1-c][1,4]oxazine-9,3'-pyrrolidine]-2-carboxamide hydrobromide

N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7-dihydro-4H-spiro[pyrimido[2,1-c][1,4]oxazine-9,3'-pyrrolidine]-2-carboxamide hydrobromide

A

Ethyl 2-(2-(4-fluorobenzylcarbamoyl)-3-hydroxy-4-oxo-6,7-dihydro-4H-spiro[pyrimido[2,1-c][1,4]oxazine-9,3'-pyrrolidine]-1'-yl)-2-oxoacetate

Ethyl 2-(2-(4-fluorobenzylcarbamoyl)-3-hydroxy-4-oxo-6,7-dihydro-4H-spiro[pyrimido[2,1-c][1,4]oxazine-9,3'-pyrrolidine]-1'-yl)-2-oxoacetate

B

N-(4-Fluorobenzyl)-3-hydroxy-1'-(5-methyl-1,3,4-oxadiazole-2-carbonyl)-4-oxo-6,7-dihydro-4H-spiro[pyrimido[2,1-c][1,4]oxazine-9,3'-pyrrolidine]-2-carboxamide

N-(4-Fluorobenzyl)-3-hydroxy-1'-(5-methyl-1,3,4-oxadiazole-2-carbonyl)-4-oxo-6,7-dihydro-4H-spiro[pyrimido[2,1-c][1,4]oxazine-9,3'-pyrrolidine]-2-carboxamide

Conditions
ConditionsYield
Stage #1: 5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt With oxalyl dichloride; N,N-dimethyl-formamide In dichloromethane at 20℃; for 1h;
Stage #2: N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7-dihydro-4H-spiro[pyrimido[2,1-c][1,4]oxazine-9,3'-pyrrolidine]-2-carboxamide hydrobromide With triethylamine In dichloromethane at 20℃; for 18h;
A 35%
B 56%
5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

(S)-2-(6-(aminomethyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid

(S)-2-(6-(aminomethyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid

(S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((5-methyl-1,3,4-oxadiazole-2-carboxamido)methyl)pyridin-3-yl)acetic acid

(S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((5-methyl-1,3,4-oxadiazole-2-carboxamido)methyl)pyridin-3-yl)acetic acid

Conditions
ConditionsYield
Stage #1: 5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt With oxalyl dichloride In dichloromethane at 20℃; for 1h;
Stage #2: (S)-2-(6-(aminomethyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid With N-ethyl-N,N-diisopropylamine In tetrahydrofuran; water at 20℃; for 1.5h;
35.9%
5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

C38H48N6O7S2*ClH

C38H48N6O7S2*ClH

C42H50N8O9S2

C42H50N8O9S2

Conditions
ConditionsYield
With 1-hydroxy-7-aza-benzotriazole; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In dichloromethane at 30℃; for 4h; Inert atmosphere;30%
5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

2-(2-amino-(1,3-d6-propan)-2-yl)-N-(4-fluorobenzyl-d6)-5-hydroxy-1-(methyl-d3)-6-oxo-1,6-dihydropyrimidine-4-carboxamide
1100750-76-2

2-(2-amino-(1,3-d6-propan)-2-yl)-N-(4-fluorobenzyl-d6)-5-hydroxy-1-(methyl-d3)-6-oxo-1,6-dihydropyrimidine-4-carboxamide

N-(2-(4-(4-fluoro(benzyl-d6)carbamoyl)-5-hydroxy-1-(methyl-d3)-6-oxo-1,6-dihydropyrimidin-2-yl)-(1,3-d6-propan)-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide
1100751-07-2

N-(2-(4-(4-fluoro(benzyl-d6)carbamoyl)-5-hydroxy-1-(methyl-d3)-6-oxo-1,6-dihydropyrimidin-2-yl)-(1,3-d6-propan)-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide

Conditions
ConditionsYield
With HATU In N,N-dimethyl-formamide at 0℃; for 3h;25%
5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

1-methyl-1-(4-nitro-phenyl)-ethylamine
3276-37-7

1-methyl-1-(4-nitro-phenyl)-ethylamine

5-methyl-N-(2-(4-nitrophenyl)propan-2-yl)-1,3,4-oxadiazole-2-carboxamide

5-methyl-N-(2-(4-nitrophenyl)propan-2-yl)-1,3,4-oxadiazole-2-carboxamide

Conditions
ConditionsYield
Stage #1: 5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt With oxalyl dichloride; N,N-dimethyl-formamide for 1h; Cooling with ice;
Stage #2: 1-methyl-1-(4-nitro-phenyl)-ethylamine With 4-methyl-morpholine for 2h; Cooling with ice;
20%
5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

3β-O-(3',3'-dimethylsuccinyl)-17β-(methylamino)-21-oxolup-18-ene
1169849-35-7

3β-O-(3',3'-dimethylsuccinyl)-17β-(methylamino)-21-oxolup-18-ene

3β-O-(3',3'-dimethylsuccinyl)-17β-[methyl-(5-methyl-[1,3,4]oxadiazole-2-carbonyl)-amino]-21-oxolup-18-ene
1169850-90-1

3β-O-(3',3'-dimethylsuccinyl)-17β-[methyl-(5-methyl-[1,3,4]oxadiazole-2-carbonyl)-amino]-21-oxolup-18-ene

Conditions
ConditionsYield
Stage #1: 5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt With oxalyl dichloride; N,N-dimethyl-formamide In acetonitrile at 0℃; for 0.833333h;
Stage #2: 3β-O-(3',3'-dimethylsuccinyl)-17β-(methylamino)-21-oxolup-18-ene With triethylamine In tetrahydrofuran; acetonitrile at 20℃; for 3.5h;
16%
Stage #1: 5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt With oxalyl dichloride; N,N-dimethyl-formamide In acetonitrile at 0℃; for 0.833333h;
Stage #2: 3β-O-(3',3'-dimethylsuccinyl)-17β-(methylamino)-21-oxolup-18-ene With triethylamine In tetrahydrofuran; acetonitrile at 20℃; for 3.5h;
16%
5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

(S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((methylamino)methyl)pyridin-3-yl)acetic acid

(S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((methylamino)methyl)pyridin-3-yl)acetic acid

(S)-2-(tert-butoxy)-2-(6-((N,5-dimethyl-1,3,4-oxadiazole-2-carboxamido)methyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid

(S)-2-(tert-butoxy)-2-(6-((N,5-dimethyl-1,3,4-oxadiazole-2-carboxamido)methyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methylpyridin-3-yl)acetic acid

Conditions
ConditionsYield
Stage #1: 5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt With oxalyl dichloride In dichloromethane at 20℃; for 1h;
Stage #2: (S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(4-(4-fluorophenethoxy)phenyl)-2-methyl-6-((methylamino)methyl)pyridin-3-yl)acetic acid In dichloromethane at 20℃; for 2h;
13.86%
5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

N-(4-fluorobenzyl)-3'-hydroxy-4'-oxo-4',6',7',8'-tetrahydrospiro[piperidine-4,9'-pyrazino[1,2-a]pyrimidine]-2'-carboxamide hydrobromide

N-(4-fluorobenzyl)-3'-hydroxy-4'-oxo-4',6',7',8'-tetrahydrospiro[piperidine-4,9'-pyrazino[1,2-a]pyrimidine]-2'-carboxamide hydrobromide

N-(4-Fluorobenzyl)-3'-hydroxy-1-(5-methyl-1,3,4-oxadiazole-2-carbonyl)-4'-oxo-4',6',7',8'-tetrahydrospiro[piperidine-4,9'-pyrazino[1,2-a]pyrimidine]-2'-carboxamide

N-(4-Fluorobenzyl)-3'-hydroxy-1-(5-methyl-1,3,4-oxadiazole-2-carbonyl)-4'-oxo-4',6',7',8'-tetrahydrospiro[piperidine-4,9'-pyrazino[1,2-a]pyrimidine]-2'-carboxamide

Conditions
ConditionsYield
Stage #1: 5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt With oxalyl dichloride; N,N-dimethyl-formamide In dichloromethane at 20℃; for 0.5h;
Stage #2: N-(4-fluorobenzyl)-3'-hydroxy-4'-oxo-4',6',7',8'-tetrahydrospiro[piperidine-4,9'-pyrazino[1,2-a]pyrimidine]-2'-carboxamide hydrobromide With N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃;
9%
5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

(S)-2-(6-(acetamidomethyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(2-(4-fluoro-2-methylbenzyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid

(S)-2-(6-(acetamidomethyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(2-(4-fluoro-2-methylbenzyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid

(S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(2-(4-fluoro-2-methylbenzyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-methyl-6-((5-methyl-1,3,4-oxadiazole-2-carboxamido)methyl)pyridin-3-yl)acetic acid

(S)-2-(tert-butoxy)-2-(4-(4,4-dimethylpiperidin-1-yl)-5-(2-(4-fluoro-2-methylbenzyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-methyl-6-((5-methyl-1,3,4-oxadiazole-2-carboxamido)methyl)pyridin-3-yl)acetic acid

Conditions
ConditionsYield
Stage #1: 5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt With oxalyl dichloride In dichloromethane for 1h;
Stage #2: (S)-2-(6-(acetamidomethyl)-4-(4,4-dimethylpiperidin-1-yl)-5-(2-(4-fluoro-2-methylbenzyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)-2-methylpyridin-3-yl)-2-(tert-butoxy)acetic acid With triethylamine In dichloromethane at 20℃; for 2h;
8.49%
2-(1-amino-1-methyl-ethyl)-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-4-pyrimidinecarboxamide
518048-03-8

2-(1-amino-1-methyl-ethyl)-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-4-pyrimidinecarboxamide

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

raltegravir
518048-05-0

raltegravir

Conditions
ConditionsYield
Stage #1: 5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt With 4-methyl-morpholine; pivaloyl chloride In 1-methyl-pyrrolidin-2-one; acetonitrile at 0℃; for 6.16667h;
Stage #2: 2-(1-amino-1-methyl-ethyl)-N-[(4-fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-4-pyrimidinecarboxamide With 4-methyl-morpholine In 1-methyl-pyrrolidin-2-one; acetonitrile at 20℃; for 16h;
5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

2,2-dimethyl-propionic acid 2-(1-amino-1-methyl-ethyl)-4-(4-fluorobenzylcarbamoyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-5-yl ester
1172131-64-4

2,2-dimethyl-propionic acid 2-(1-amino-1-methyl-ethyl)-4-(4-fluorobenzylcarbamoyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-5-yl ester

raltegravir
518048-05-0

raltegravir

Conditions
ConditionsYield
Stage #1: 5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt With 4-methyl-morpholine; pivaloyl chloride In 1-methyl-pyrrolidin-2-one; acetonitrile at -10℃; for 15h; Inert atmosphere;
Stage #2: 2,2-dimethyl-propionic acid 2-(1-amino-1-methyl-ethyl)-4-(4-fluorobenzylcarbamoyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-5-yl ester In 1-methyl-pyrrolidin-2-one; acetonitrile at 20℃;
Stage #3: With ammonium hydroxide In isopropyl alcohol at 20℃; for 1h;
5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt
888504-28-7

5-methyl-1,3,4-oxadiazole-2-carboxylic acid potassium salt

cis-7-methyl-N-(3,4,5-trifluorophenyl)-2,3,3a,4,10,10a-hexahydro-1H,7H-dipyrrolo[3,4-b:3',4'-f][1,4,5]oxathiazocine-8-carboxamide 5,5-dioxide hydrochloride

cis-7-methyl-N-(3,4,5-trifluorophenyl)-2,3,3a,4,10,10a-hexahydro-1H,7H-dipyrrolo[3,4-b:3',4'-f][1,4,5]oxathiazocine-8-carboxamide 5,5-dioxide hydrochloride

cis-7-methyl-2-(5-methyl-1,3,4-oxadiazole-2-carbonyl)-N-(3,4,5-trifluorophenyl)-2,3,3a,4,10,10a-hexahydro-1H,7H-dipyrrolo[3,4-b:3',4'-f][1,4,5]oxathiazocine-8-carboxamide 5,5-dioxide

cis-7-methyl-2-(5-methyl-1,3,4-oxadiazole-2-carbonyl)-N-(3,4,5-trifluorophenyl)-2,3,3a,4,10,10a-hexahydro-1H,7H-dipyrrolo[3,4-b:3',4'-f][1,4,5]oxathiazocine-8-carboxamide 5,5-dioxide

Conditions
ConditionsYield
With 2-(2,3-dihydro-1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V); triethylamine In N,N-dimethyl-formamide at 20℃; for 1h;7.23 mg

888504-28-7Relevant articles and documents

Design, Synthesis, and Study of the Insecticidal Activity of Novel Steroidal 1,3,4-Oxadiazoles

Bai, Hangyu,Jiang, Weiqi,Li, Qi,Li, Tian,Ma, Shichuang,Shi, Baojun,Wu, Wenjun

, p. 11572 - 11581 (2021/10/12)

A series of novel steroidal derivatives with a substituted 1,3,4-oxadiazole structure was designed and synthesized, and the target compounds were evaluated for their insecticidal activity against five aphid species. Most of the tested compounds exhibited potent insecticidal activity against Eriosoma lanigerum (Hausmann), Myzus persicae, and Aphis citricola. Compounds 20g and 24g displayed the highest activity against E. lanigerum, showing LC50 values of 27.6 and 30.4 μg/mL, respectively. Ultrastructural changes in the midgut cells of E. lanigerum were detected by transmission electron microscopy, indicating that these steroidal oxazole derivatives might exert their insecticidal activity by destroying the mitochondria and nuclear membranes in insect midgut cells. Furthermore, a field trial showed that compound 20g exhibited effects similar to those of the positive controls chlorpyrifos and thiamethoxam against E. lanigerum, reaching a control rate of 89.5% at a dose of 200 μg/mL after 21 days. We also investigated the hydrolysis and metabolism of the target compounds in E. lanigerum by assaying the activities of three insecticide-detoxifying enzymes. Compound 20g at 50 μg/mL exhibited inhibitory action on carboxylesterase similar to the known inhibitor triphenyl phosphate. The above results demonstrate the potential of these steroidal oxazole derivatives to be developed as novel pesticides.

Preparation method of pyrimidinone amide type compound

-

Paragraph 0042; 0043; 0046, (2018/10/19)

The invention discloses a pyrimidinone amide type compound and a preparation method thereof. A pyrimidinone compound is taken as a starting material and is subjected to four-step chemical conversion to obtain TN-A005 and an analogue thereof, and an intermediate can be prepared from methyl tetrazole. A one-pot method is used for feeding in the whole preparation process, post-treatment purificationof each step is recrystallization or dispersion washing, the use of means such as silica gel column chromatography is avoided, the preparation technology is greatly simplified, the preparation efficiency is improved, and the total yield can reach 50%. The method is simple and convenient in preparation steps and can improve the preparation efficiency.

3. 4 - diphenyl - 4H - 1, 2, 4 - triazole derivative and its preparation method and application (by machine translation)

-

Paragraph 0243; 0274; 0275; 0276, (2017/07/01)

The invention discloses 3, 4 - diphenyl - 4H - 1, 2, 4 - triazole derivative and its preparation method and application. In particular, the invention relates to the formula (I) structure of 3, 4 - diphenyl - 4H - 1, 2, 4 - triazole derivatives, its stereoisomers or its pharmaceutically acceptable salt, formula (I) in the definition of each substituent is as defined in the specification. These structure of novel compound with heat shock protein HSP90 inhibitory activity, can be used for treating cancer, neurodegenerative diseases, inflammatory diseases, autoimmune diseases, ischemic brain injury and the like, it has broad application prospects. (by machine translation)

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 888504-28-7